Skip to main content
×
×
Home

Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder

  • Erik Joas (a1), Alina Karanti (a1), Jie Song (a2), Guy M. Goodwin (a3), Paul Lichtenstein (a2) and Mikael Landén (a4)...
Abstract
Background

Clinical trials have examined the efficacy of drugs to prevent relapse in patients with bipolar disorder, however, their design often limits generalisation to routine clinical practice.

Aims

To estimate the effectiveness of drugs used for maintenance treatment in bipolar disorder.

Method

We used national registers to identify 35022 individuals diagnosed with bipolar disorder and information on lithium, valproate, carbamazepine, lamotrigine, quetiapine and olanzapine treatment from 2006 to 2009. The main outcome was psychiatric hospital admissions. We used stratified cox regression to compare periods on and off medication within the same individual.

Results

Medication with lithium, valproate, lamotrigine, olanzapine and quetiapine was associated with reduced rates of admission to hospital. Lithium was more effective than quetiapine and olanzapine. The effects of specific drugs depended on the polarity of the mood episode.

Conclusions

Our findings complement results from randomised controlled trails, but suggest that lithium is more effective than both quetiapine and olanzapine in routine clinical practice.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder
      Available formats
      ×
Copyright
Corresponding author
Mikael Landén, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Gothenburg University, Gothenburg, Su Sahlgrenska 41345, Sweden. Email: mikael.landen@neuro.gu.se
Footnotes
Hide All

Declaration of interest

A.K. declares that, over the past 36 months, she has received lecture honoraria from Eli Lilly Sweden. M.L. declares that, over the past 36 months, he has received lecture honoraria from Biophausia Sweden, Servier Sweden, AstraZeneca. G.M.G. has held grants from Servier, received honoraria for speaking or chairing educational meetings from Abbvie, AZ, GSK, Lilly, Lundbeck, Medscape, Servier, and advised AZ, Cephalon/Teva, Lundbeck, Merck, Otsuka, P1vital, Servier, Sunovion and Takeda, and holds shares in P1vital.

Footnotes
References
Hide All
1 National Institute for Clinical Excellence (NICE). Bipolar Disorder: Assessment and Management. NICE, 2014 (https://www.nice.org.uk/guidance/cg185).
2 Miura, T, Noma, H, Furukawa, TA, Mitsuyasu, H, Tanaka, S, Stockton, S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014; 1: 351–9.
3 Goodwin, FK, Jamison, KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression: Bipolar Disorders and Recurrent Depression. Oxford University Press, 2007.
4 Rothwell, PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005; 365: 8293.
5 Licht, R, Gouliaev, G, Vestergaard, P, Frydenberg, M. Generalisability of results from randomised drug trials. A trial on antimanic treatment. Br J Psychiatry 1997; 170: 264–7.
6 Tohen, M, Greil, W, Calabrese, JR, Sachs, GS, Yatham, LN, Oerlinghausen, BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281–90.
7 Geddes, JR, Goodwin, GM, Rendell, J, Azorin, J-M, Cipriani, A, Ostacher, MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385–95.
8 Licht, RW, Nielsen, JN, Gram, LF, Vestergaard, P, Bendz, H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483–93.
9 Whitaker, R, Cosgrove, L. Psychiatry Under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform. Palgrave Macmillan, 2015.
10 Kessing, LV, Hellmund, G, Geddes, JR, Goodwin, GM, Andersen, PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 5763.
11 Kessing, LV, Hellmund, G, Andersen, PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 2012; 26: 644–52.
12 Simhandl, C, König, B, Amann, BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry 2014; 75: 254–63.
13 Lichtenstein, P, Halldner, L, Zetterqvist, J, Sjolander, A, Serlachius, E, Fazel, S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367: 2006–14.
14 Socialstyrelsen (The National Board of Health and Welfare). Uppgifter om Psykiatrisk vård i Patientregistret [Data on Psychiatric Care in the Patient Register]. Socialstyrelsen, 2014 (http://www.socialstyrelsen.se/publikationer2014/2014-2-14).
15 Karanti, A, Bobeck, C, Osterman, M, Kardell, M, Tidemalm, D, Runeson, B, et al. Gender differences in the treatment of patients with bipolar disorder: A study of 7354 patients. J Affect Disord 2015; 174: 303–9.
16 Sellgren, C, Landen, M, Lichtenstein, P, Hultman, CM, Langstrom, N. Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden. Acta Psychiatr Scand 2011; 124: 447–53.
17 World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD–8). WHO, 1967.
18 World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD–9). WHO, 1978.
19 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
20 Fazel, S, Zetterqvist, J, Larsson, H, Långström, N, Lichtenstein, P. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet 2014; 384: 1206–14.
21 Molero, Y, Lichtenstein, P, Zetterqvist, J, Gumpert, CH, Fazel, S. Selective serotonin reuptake inhibitors and violent crime: a cohort study. PLoS Med 2015; 12: e1001875.
22 Benjamini, Y, Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289300.
23 Leifeld, P. texreg: Conversion of statistical model output in R to LATEX and HTML tables. J Stat Softw 2013; 55: 124.
24 Hayes, JF, Marston, L, Walters, K, Geddes, JR, King, M, Osborn, DPJ. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 2016; 15: 53–8.
25 Vieta, E, Günther, O, Locklear, J, Ekman, M, Miltenburger, C, Chatterton, ML, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011; 14: 1029–49.
26 Smith, LA, Cornelius, V, Warnock, A, Bell, A, Young, AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorders 2007; 9: 394412.
27 Deshauer, D, Fergusson, D, Duffy, A, Albuquerque, J, Grof, P. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. Bipolar Disord 2005; 7: 382–7.
28 Goodwin, GM, Bowden, CL, Calabrese, JR, Grunze, H, Kasper, S, White, R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432–41.
29 Hirschfeld, R, Kasper, S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004; 7: 507–22.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 148 *
Loading metrics...

Abstract views

Total abstract views: 198 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 25th May 2018. This data will be updated every 24 hours.

Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder

  • Erik Joas (a1), Alina Karanti (a1), Jie Song (a2), Guy M. Goodwin (a3), Paul Lichtenstein (a2) and Mikael Landén (a4)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *